for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

U.S. Supreme Court rebuffs Merck appeal in hepatitis C patent fight with Gilead

Jan 19 (Reuters) - The U.S. Supreme Court on Tuesday rejected Merck & Co Inc’s bid to revive a $2.54 billion jury verdict it won against rival drugmaker Gilead Sciences Inc for infringing a patent in a dispute over a blockbuster hepatitis C treatment.

The justices declined to take up Merck’s appeal of a lower court’s ruling that overturned the massive damages verdict after finding that Merck’s patent was invalid. (Reporting by Andrew Chung in New York; Editing by Will Dunham)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up